arrow_back Back to App

Improved Drug Patent Coordination: Agency Collaboration for Safety

This new law establishes a task force to streamline information exchange between the Patent Office and the Food and Drug Administration. This will lead to more precise decisions regarding patents for drugs and biological products, potentially impacting the availability and safety of new therapies. Citizens may benefit from faster market introduction of innovative drugs while maintaining high safety standards.
Key points
Establishment of an interagency task force to coordinate the activities of the Patent Office and the Food and Drug Administration regarding drug patents.
Improved information and data exchange between these agencies to assist in more accurate patent application evaluations.
Implementation of confidentiality protocols to ensure the security of information related to drugs and biological products.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4570
Sponsor: Rep. Neguse, Joe [D-CO-2]
Process start date: 2025-07-21
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Interagency Patent Coordination and Improvement Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4570.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-07-21.

What are the main provisions?

Key points include:

  • Establishment of an interagency task force to coordinate the activities of the Patent Office and the Food and Drug Administration regarding drug patents.
  • Improved information and data exchange between these agencies to assist in more accurate patent application evaluations.
  • Implementation of confidentiality protocols to ensure the security of information related to drugs and biological products.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Neguse, Joe [D-CO-2].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health Courts and Law